Researchers in Spain and Switzerland have identified a molecule called OLE that reprograms the brain's immune cells — microglia — to resume their protective role against Alzheimer's disease. In animal models, the treatment reduced toxic beta-amyloid plaque buildup by 42% and improved memory function. The findings, published in Cell Death and Disease, offer a new approach that targets immune cells rather than plaques directly.
A new study published in medical journals finds that people who regularly monitor their blood pressure at home have significantly fewer heart attacks and strokes compared to those who rely only on clinic measurements. The research tracked thousands of patients over several years and found that home monitoring, combined with timely medication adjustments, reduced major cardiovascular events by roughly 20%. The findings support broader adoption of home blood pressure monitoring as a low-cost intervention.
A new study presented at the Alzheimer's Association International Conference found that older adults who walk fast and maintain strong mobility in their 80s show a 40% lower risk of cognitive decline over seven years. Researchers tracked 2,400 participants and found that gait speed was a stronger predictor of brain health than many traditional risk factors. The findings suggest mobility-focused interventions could play a role in dementia prevention.
A new study led by Brown University researchers found that older adults who received the Shingrix shingles vaccine had a 24% lower risk of developing dementia over four years compared to unvaccinated peers. Published in the Annals of Internal Medicine, the study examined elderly nursing home residents who received at least one dose of the vaccine after entering a skilled nursing facility. The research adds to a growing body of evidence connecting viral infection prevention with cognitive decline, offering a potential low-cost intervention for reducing dementia risk in vulnerable populations.
The CDC is tapping $107 million in emergency funding for Ebola response in the Democratic Republic of Congo and Uganda after at least 30 people died in a displaced persons camp in northeastern Congo since May. Camp officials called the death rate unprecedented. Separately, a new GLP-1 pill for diabetes was presented at ADA 2026, and Baylor researchers found a promising new approach to combat Alzheimer's and Parkinson's.
An FDA advisory panel endorsed a new mRNA-based influenza vaccine, despite HHS Secretary Robert F. Kennedy Jr.'s public skepticism of the technology. The endorsement could lead to the first mRNA flu shot on the US market. Separately, more than 770,000 children nationwide have lost access to SNAP food benefits following Trump administration changes to eligibility rules, with Arizona seeing the largest percentage decline. Research also showed that the shingles vaccine is linked to lower dementia risk in older adults, and a study found Nordic walking reduces depression symptoms in as little as five weeks.
Two patients with a severe autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD) have remained in remission for more than 15 years after receiving a donor stem cell transplant, according to a study published in Nature. Researchers at IRCCS San Raffaele Hospital in Milan used allogeneic hematopoietic stem-cell transplants—using stem cells from a donor—to treat the condition for the first time. The results suggest the therapy may offer a durable, one-time treatment option for certain autoimmune diseases where existing therapies require lifelong immunosuppression.
A copper-based compound has restored the brain's ability to clear toxic Alzheimer's proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments, pointing to a potentially fast-tracked new treatment. Separately, GLP-1 drugs like Ozempic and Wegovy were linked to a 30% lower breast cancer risk, while semaglutide showed stronger protection against bone fractures. An AI-designed universal coronavirus vaccine passed its first human trial, generating immune responses against multiple variants.
A major new study published by Medical News Today finds that GLP-1 receptor agonist drugs like Ozempic and Wegovy reduce the risk of four types of cancer by 50% or more. The research adds to growing evidence that these medications, already widely used for weight loss and diabetes management, offer broader health benefits. Meanwhile, the FDA proposed a ban on bulk compounding of semaglutide and tirzepatide, and the first-ever AI-designed vaccine entered human trials.
A new study finds that GLP-1 weight loss drugs like Ozempic and Wegovy slash the risk of four types of cancer by 50% or more, expanding their potential health benefits beyond diabetes and weight management. The FDA proposed banning bulk compounding of semaglutide and tirzepatide, and glucosamine supplements were linked to faster dementia progression in a separate study.